KẾT QUẢ HÓA XẠ TRỊ ĐỒNG THỜI TRIỆT CĂN UNG THƯ THỰC QUẢN BẰNG PHÁC ĐỒ CAPOX TẠI BỆNH VIỆN K

Abstract

Objective: To evaluate treatment response and adverse events in patients with esophageal cancer undergoing definitive concurrent chemoradiotherapy with the CAPOX regimen at K Hospital. Subjects and Methods: This descriptive study included 102 patients with unresectable esophageal cancer treated at K Hospital. Results: The mean age was 61.7 ± 7.9 years. The male-to-female ratio was 50:1. The middle third of the esophagus was the most frequent tumor site (44.2%). Disease stages II, III, and IVA accounted for 33.3%, 62.7%, and 3.9% of cases, respectively. The mean chemotherapy dose intensity was 95.0 ± 1.5%. Radiotherapy interruptions < 7 days and ≥ 7 days were 53.9% and 46.1%, respectively. The rates of complete response, partial response, stable disease, and progressive disease were 31.4%, 58.8%, 6.9%, and 2.9%, respectively. Response rates were significantly higher in earlier-stage tumors and in patients without regional lymph node metastasis (p < 0.05). Response rates were higher in patients with earlier-stage disease and without regional lymph node metastasis (p < 0.05). The most common hematologic toxicities were: anemia (43.1%), leukopenia (32.3%), and thrombocytopenia (36.3%). Early radiation-related complications included esophagitis (52.0%), dermatitis (48.1%), pneumonitis (12.8%), and esophageal fistula (1.0%). Conclusion: Definitive concurrent chemoradiotherapy with the CAPOX regimen achieved favorable response outcomes with an acceptable toxicity profile.